The Improving Landscape of HCV Therapy: The Opportunity to Eliminate a Scrouge


CLICK HERE To View On-Demand Symposium

About the Program:

Program Overview:

In recent years, significant progress has been made regarding the therapeutic options for chronic hepatitis C (CHC). This progress has the potential to significantly improve treatment success and tolerability rates; however, in order for that to occur, health care providers (HCPs) who manage CHC patients must be aware of the full range of treatment options currently available or in development. Some of these options, e.g., the HCV protease inhibitors, significantly improve treatment efficacy but not tolerability and adverse events. Other options, currently in development, have the potential to not only improve treatment efficacy, tolerability and adverse events, but also to shorten treatment duration and limit or eliminate the need for use of pegylated interferon and ribavirin.

Due to the improving landscape of HCV therapy, in order to appropriately assess, manage and treat CHC patients, HCPs must be aware of: (1) current treatment options for CHC, including issues that limit their acceptance and efficacy; (2) HCV therapies in development that are likely to change the treatment paradigm for CHC patients; (3) treatment and patient factors that predict and contribute to treatment success; and (4) when and how to use the HCV therapies that are currently available or likely to be approved in the near future.

HCPs without this knowledge and ability have professional practice gaps that are likely to adversely affect CHC treatment outcomes. This CME program has been designed to address these practice gaps by updating clinicians on recent advances in CHC treatment, especially newer therapies. National thought leaders will lead participants through an overview of the current CHC treatment paradigms and present detailed clinical trial data on newly approved therapies and strategies and discuss products in development that are expected to shape treatment decisions in the near future. It is the goal of this program to address treatment gaps and provide clinicians with the tools needed to adjust their behavior so that they can provide optimal care to patients with CHC, thereby reducing morbidity and mortality associated with CHC.

Back to Top   

Target Audience:

The audience for this program will consist of health care providers who care for patients with CHC, including internal medicine and family practice physicians, hepatologists, gastroenterologists, and infectious disease specialists, along with nurse practitioners, physician assistants, and nurses.

Back to Top

Program Objectives:

Upon completion of this activity, participants should be able to:

  • Provide the current standard of care for chronic HCV to patients; 

  • Discuss potential risks and benefits of HCV treatment to patients;

  • Identify individual patient characteristics and preferences that should guide the decision to immediately start or defer HCV treatment;

  • Be prepared to use currently in development direct-acting antiviral agents for chronic HCV;

  • Describe how the direct-acting antiviral agents may affect future HCV treatment paradigms and the chance for HCV elimination.

Release Date: December 18, 2012

Expiration Date: December 18, 2013

Estimated time to complete this Web Symposium: 2 hours, 15 minutes

Media: Internet

Back to Top

Course Directors:

Nezam H. Afdhal, MD, MD
Associate Professor of Medicine,
Harvard School of Medicine Chief of Hepatology,
Director of Liver Center,
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Mark Sulkowski, MD
Professor of Medicine and Medical Director,
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Back to Top 


Natarajan Ravendhran, MD, FACG
Chief, Department of Gastroenterology & Liver Diseases 
St. Agnes Healthcare
Baltimore, Maryland


Vinod Rustgi, MD
Clinical Professor of Medicine and Surgery,
Georgetown University Medical Center
Washington, DC
Clinical Professor,
Virginia Commonwealth University
Richmond, Virginia

Rowit Talwani, MD
Assistant Professor of Medicine,
Division of Infectious Diseases
University of Maryland Medical Center
Baltimore, Maryland

Back to Top


Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc.. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation:

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) assesses conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr. Nezam Afdhal:

  • Consulting Fees: Gilead, Echosens, GSK, Vertex, Novartis, BI, Ligand, Springbank, Medgenics
  • Contracted Research: Schering Plough/Merck, Novartis, GSK, Echosens, Vertex, Gilead, Quest, Pharmasett, Abbott
  • Stock Options: Springbank, Medgenics

Dr. Natarajan Ravendhran:

  • Contracted Research: Gilead, BMS, Merck
  • Consulting Fees: Vertex, Merck, Gilead, Onyx

Dr. Vinod Rustgi:

  • Consulting Fees: Novartis, Merck, Tibotec
  • Fees for Non-CME/CE Services: Genentech, Onyx, Gilead, Otsuka
  • Contracted Research: Novartis, BMS, Gilead 

Dr. Mark Sulkowski:

  • Contracted Research: Abbott BIPI, BMS, Gilead, Janssen, Merck, Roche, Vertex
  • Consulting Fees: Abbott BIPI, BMS, Gilead, Janssen, Merck, Roche, Vertex

Dr. Rohit Talwani:

  • Fees for Non-CME/CE Services: Merck
  • Contracted Research: Vertex

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following planners and managers:, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP, Patricia Staples, MSN, NP-C, CCRN and Eric Peterson, EdM, FACEHP,hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, PIM, ViralEd, Inc., and commercial grantors do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, ViralEd, Inc.,  and commercial grantors. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Instructions for Participation and Credit

There are no fees for participating and receiving credit for this activity. During the period, Date December 18, 2012 through December 18, 2013, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form.

To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on the Submit Post-test at the bottom of the page. Your post-test will automatically be graded.

If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.

You may complete the Post-test on-line at

  • Click on "Find Post-Test/Evaluation by Course" on the navigation menu
  • Search by project ID: 8987
  • Upon successfully completing the Post-test and Evaluation form, your certificate will be made available immediately.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

Back to Top

Commercial Support Acknowledgement: 

Supported by an unrestricted educational grant from Janssen Therapeutics and Gilead Sciences Medical Affairs

  PIM_small    VE logo 300px

Jointly Sponsored by Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc..
in collaboration with The Postgraduate Institute for Medicine

Click logo above to contact Annenberg Center, PIM or ViralEd.

Prepare to print

Share this page:

Get link code to this page     

Back to Top